Filana Therapeutics, Inc. (FLNA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 35/100 (MEDIUM), 20.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 13.06% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
- Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
- Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
- Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
- Data I/O And 2 Other Promising Penny Stocks To Watch
- Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
- Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Filana Therapeutics, Inc..
Full FLNA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.